European Medicines Agency approves first malaria vaccineBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4067 (Published 27 July 2015) Cite this as: BMJ 2015;351:h4067
- Nigel Hawkes
A vaccine against malaria has gained regulatory approval for the first time. Mosquirix, developed by GlaxoSmithKline, has been approved by the European Medicines Agency after trials showed modest but worthwhile effects in children aged between 6 weeks and 17 months.
The success came after years of largely unavailing effort to develop a vaccine against a disease that still kills more than 600 000 people a year, 90% of them in Africa and the vast …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial